NCT04147338View on ClinicalTrials.gov

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

440

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

September 13, 2021

Study Completion Date

December 7, 2021

Conditions

Healthy

Interventions

DRUG

Guselkumab

Guselkumab will be administered subcutaneously.

Trial Locations (2)

68167

CRS Clinical Research Services, Mannheim

85283

Celerion, Tempe

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04147338 - A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants | Biotech Hunter | Biotech Hunter